ADUS
Addus HomeCare Corporation
ADUS has the edge over NVO overall, supported by stronger valuation and stronger fundamentals.
NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
ADUS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
ADUS's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ADUS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 17x | $124 | — |
| Current | 21x | $124 | — |
| Cheap | 24x | $146 | +18% |
| Fair | 30x | $180 | +46% |
| Expensive | 48x | $286 | +131% |
Historical ranges are pointers, not guarantees.
ADUS's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 17x next year's earnings.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over ADUS in the historical PE scenario, which offers more potential upside but is not a forecast.
ADUS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
ADUS has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ADUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.47 | +24% |
| Q3 2026 | $6.01 | +29% |
| Q2 2026 | $5.71 | +26% |
| Q1 2026 | $5.42 | +23% |
| Q4 2025 | $5.22 | +23% |
| Q3 2025 | $4.66 | +6.9% |
| Q2 2025 | $4.52 | +7.4% |
| Q1 2025 | $4.42 | +10% |
| Q4 2024 | $4.23 | +10% |
ADUS's earnings per share have climbed steadily: $6.01 over the past year, up 29% from the year before, and higher year over year every quarter since late 2020.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over ADUS on earnings, with stronger typical year-over-year growth.
ADUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $387.7M | +7% |
| Q2 2026 | $377.4M | +8% |
| Q1 2026 | $363.6M | +7.7% |
| Q4 2025 | $373.1M | +26% |
| Q3 2025 | $362.3M | +25% |
| Q2 2025 | $349.4M | +22% |
| Q1 2025 | $337.7M | +20% |
| Q4 2024 | $297.1M | +7.5% |
ADUS's revenue has grown year over year every quarter since late 2020: $388M last quarter, up 7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | +1.2 points |
| Q2 2026 | 10% | +0.9 points |
| Q1 2026 | 9.4% | +0.3 points |
| Q4 2025 | 11% | +2.3 points |
| Q3 2025 | 9.1% | +0.1 points |
| Q2 2025 | 9.4% | +0.3 points |
| Q1 2025 | 9% | +0.6 points |
| Q4 2024 | 9.1% | -1.1 points |
ADUS's operating margin was 10% last quarter, up 1.2 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over ADUS on profitability, with a higher operating margin.
ADUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $38.8M | -21% |
| Q2 2026 | $38.7M | +82% |
| Q1 2026 | $50.7M | +197% |
| Q4 2025 | $16.1M | +85% |
| Q3 2025 | $49.3M | +5.9% |
| Q2 2025 | $21.3M | +20% |
| Q1 2025 | $17.1M | -54% |
| Q4 2024 | $8.7M | -65% |
ADUS generated $144M in free cash flow over the past year, up 50% from the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
ADUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +102K shares |
| 1 year | +1% | +184K shares |
| 3 years | +14% | +2.3M shares |
| 5 years | +16% | +2.5M shares |
| Available history | +17% | +2.7M shares |
ADUS has 19M diluted shares, up 1% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over ADUS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ADUS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.3x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.6x | Very low |
| Q1 2025 | 0.8x | Very low |
| Q4 2024 | 1.0x | Healthy |
ADUS has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
ADUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.4 | Neutral |
| Stochastic | 75.9 | Neutral |
ADUS's weekly RSI is 63 (neutral) and its Stochastic is 76 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ADUS PE vs Healthcare Sector
| Metric | ADUS | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 20% below |
| PE % | 8 | 29 | 21 pts below |
ADUS is trading at 21x earnings, a 20% discount to the Healthcare sector's median of 26x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over ADUS on valuation relative to its sector.
ADUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $118.8 | 4.2% above |
| 20 week MA | $116.7 | 6.1% above |
| 50 week MA | $107.7 | 15% above |
| 100 week MA | $110.0 | 13% above |
| 200 week MA | $106.5 | 16% above |
ADUS has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
ADUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $95.6 | $115.2 | +21% |
| 2021 | $115.2 | $93.3 | -19% |
| 2022 | $93.3 | $101.0 | +8.2% |
| 2023 | $101.0 | $92.9 | -8% |
| 2024 | $92.9 | $128.2 | +38% |
| 2025 | $128.2 | $110.2 | -14% |
| 2026 YTD | $110.2 | $123.7 | +12% |
ADUS has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.